579 related articles for article (PubMed ID: 25497766)
1. Efficacy and safety of rituximab in auto-immune hemolytic anemia: A meta-analysis of 21 studies.
Reynaud Q; Durieu I; Dutertre M; Ledochowski S; Durupt S; Michallet AS; Vital-Durand D; Lega JC
Autoimmun Rev; 2015 Apr; 14(4):304-13. PubMed ID: 25497766
[TBL] [Abstract][Full Text] [Related]
2. Rituximab is an effective and safe therapeutic alternative in adults with refractory and severe autoimmune hemolytic anemia.
Peñalver FJ; Alvarez-Larrán A; Díez-Martin JL; Gallur L; Jarque I; Caballero D; Díaz-Mediavilla J; Bustelos R; Fernández-Aceñero MJ; Cabrera JR;
Ann Hematol; 2010 Nov; 89(11):1073-80. PubMed ID: 20526716
[TBL] [Abstract][Full Text] [Related]
3. [Outcomes of splenectomy in relapsed/refractory autoimmune hemolytic anemia].
Fan SB; Wang ZJ; Mao Q; Tong CF; Zhai WT; Zheng YZ; Sun CX; Shi J
Zhonghua Xue Ye Xue Za Zhi; 2019 Feb; 40(2):132-136. PubMed ID: 30831628
[No Abstract] [Full Text] [Related]
4. Rituximab for immune cytopenia in adults: idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, and Evans syndrome.
Shanafelt TD; Madueme HL; Wolf RC; Tefferi A
Mayo Clin Proc; 2003 Nov; 78(11):1340-6. PubMed ID: 14601692
[TBL] [Abstract][Full Text] [Related]
5. Rituximab in auto-immune haemolytic anaemia and immune thrombocytopenic purpura: a Belgian retrospective multicentric study.
Dierickx D; Verhoef G; Van Hoof A; Mineur P; Roest A; Triffet A; Kentos A; Pierre P; Boulet D; Bries G; Lê PQ; Janssens A; Delannoy A
J Intern Med; 2009 Nov; 266(5):484-91. PubMed ID: 19549092
[TBL] [Abstract][Full Text] [Related]
6. [Successful treatment with rituximab in a patient with refractory mixed-type autoimmune hemolytic anemia].
Ono K; Sato T; Iyama S; Tatekoshi A; Hashimoto A; Kamihara Y; Horiguchi H; Kikuchi S; Takada K; Hayashi T; Miyanishi K; Sato Y; Takimoto R; Kobune M; Kato J
Rinsho Ketsueki; 2013 Nov; 54(11):2053-5. PubMed ID: 24305538
[TBL] [Abstract][Full Text] [Related]
7. [Lower dose of rituximab in the treatment of elderly autoimmune hemolytic anemia].
Zhang X; Sun J
Zhonghua Xue Ye Xue Za Zhi; 2014 Mar; 35(3):236-8. PubMed ID: 24666491
[TBL] [Abstract][Full Text] [Related]
8. [Autoimmune hemolytic anemia: diagnosis and management].
Philippe P
Presse Med; 2007 Dec; 36(12 Pt 3):1959-69. PubMed ID: 17481848
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of rituximab in autoimmune and microangiopathic hemolytic anemia: a systematic review and meta-analysis.
Chao SH; Chang YL; Yen JC; Liao HT; Wu TH; Yu CL; Tsai CY; Chou YC
Exp Hematol Oncol; 2020; 9():6. PubMed ID: 32322437
[TBL] [Abstract][Full Text] [Related]
10. Practical therapy for primary autoimmune hemolytic anemia in adults.
Fatone MC; Cirasino L
Clin Exp Med; 2023 Jul; 23(3):727-736. PubMed ID: 35980482
[TBL] [Abstract][Full Text] [Related]
11. Autoimmune hemolytic anemia.
Čermák J; Písačka M
Vnitr Lek; 2018; 64(5):514-519. PubMed ID: 30193520
[TBL] [Abstract][Full Text] [Related]
12. [Autoimmune hemolytic anemia].
Karasawa M
Nihon Rinsho; 2008 Mar; 66(3):520-3. PubMed ID: 18326320
[TBL] [Abstract][Full Text] [Related]
13. Sustained response to low-dose rituximab in idiopathic autoimmune hemolytic anemia.
Barcellini W; Zaja F; Zaninoni A; Imperiali FG; Di Bona E; Fattizzo B; Consonni D; Cortelezzi A; Zanella A
Eur J Haematol; 2013 Dec; 91(6):546-51. PubMed ID: 24033754
[TBL] [Abstract][Full Text] [Related]
14. Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: a GIMEMA study of 308 patients.
Barcellini W; Fattizzo B; Zaninoni A; Radice T; Nichele I; Di Bona E; Lunghi M; Tassinari C; Alfinito F; Ferrari A; Leporace AP; Niscola P; Carpenedo M; Boschetti C; Revelli N; Villa MA; Consonni D; Scaramucci L; De Fabritiis P; Tagariello G; Gaidano G; Rodeghiero F; Cortelezzi A; Zanella A
Blood; 2014 Nov; 124(19):2930-6. PubMed ID: 25232059
[TBL] [Abstract][Full Text] [Related]
15. Rituximab for warm-type idiopathic autoimmune hemolytic anemia: a retrospective study of 11 adult patients.
D'Arena G; Califano C; Annunziata M; Tartarone A; Capalbo S; Villani O; Amendola G; Pietrantuono G; Ferrara F; Pinto A; Musto P; D'Arco AM; Cascavilla N
Eur J Haematol; 2007 Jul; 79(1):53-8. PubMed ID: 17532766
[TBL] [Abstract][Full Text] [Related]
16. Diagnosis and treatment of autoimmune haemolytic anaemias in adults: a clinical review.
Valent P; Lechner K
Wien Klin Wochenschr; 2008; 120(5-6):136-51. PubMed ID: 18365153
[TBL] [Abstract][Full Text] [Related]
17. Alemtuzumab induced complete remission of autoimmune hemolytic anemia refractory to corticosteroids, splenectomy and rituximab.
Cheung WW; Hwang GY; Tse E; Kwong YL
Haematologica; 2006 May; 91(5 Suppl):ECR13. PubMed ID: 16709521
[TBL] [Abstract][Full Text] [Related]
18. Addition of rituximab to standard therapy improves response rate and progression-free survival in relapsed or refractory thrombotic thrombocytopenic purpura and autoimmune haemolytic anaemia.
Heidel F; Lipka DB; von Auer C; Huber C; Scharrer I; Hess G
Thromb Haemost; 2007 Feb; 97(2):228-33. PubMed ID: 17264951
[TBL] [Abstract][Full Text] [Related]
19. Rituximab is an effective and safe treatment of relapse in elderly patients with resistant warm AIHA.
Laribi K; Bolle D; Ghnaya H; Sandu A; Besançon A; Denizon N; Truong C; Pineau-Vincent F; de Materre AB
Ann Hematol; 2016 Apr; 95(5):765-9. PubMed ID: 26858026
[TBL] [Abstract][Full Text] [Related]
20. Low-dose rituximab in adult patients with idiopathic autoimmune hemolytic anemia: clinical efficacy and biologic studies.
Barcellini W; Zaja F; Zaninoni A; Imperiali FG; Battista ML; Di Bona E; Fattizzo B; Consonni D; Cortelezzi A; Fanin R; Zanella A
Blood; 2012 Apr; 119(16):3691-7. PubMed ID: 22267606
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
